drugset / Trial / NCT00083083
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Phase 2
Unknown
250 enrolled
American College of Radiology Imaging Network
National Cancer Institute (NCI) · collabRadiation Therapy Oncology Group · collab
Open-labelDiagnostic
Summary
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Timeline
- Start
- 2005-03
- Primary completion
- 2006-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Vinblastine | Small molecule | — | — |
| Background | Vinorelbine | Small molecule | — | — |